Shilov V V, Shikalova I A, Vasil'ev S A, Batotsyrenov B V, Andrianov A Iu
Klin Med (Mosk). 2013;91(2):45-8.
A total of 103 patients with acute alcoholic intoxication were examined and treated for alcohol-induced hepatic lesions. It was shown that remaxol reduced severity of metabolic disorders associated with hypoxic conditions and active lipid peroxidation and thereby decreased the frequency of alcoholic delirium to 10.8% (n=7) compared with ademetionine (10.8%, n=22). Improvement of metabolism resulted in the reduction of stay in the intensive therapy ward by 5.6+/-0.3 and 7.3+/-0.6 days after remaxol and ademetionine therapy respectively). The total duration of treatment decreased by 9.0+/-0.4 and 11.8+/-1.1 days. The use of remaxol reduced the cost of the treatment by 21.7% compared with ademetionine.
对103例急性酒精中毒患者进行了检查,并对酒精性肝损伤进行了治疗。结果表明,与腺苷蛋氨酸相比,雷美索降低了与缺氧条件和活性脂质过氧化相关的代谢紊乱的严重程度,从而将酒精性谵妄的发生率降低至10.8%(n=7)(腺苷蛋氨酸组为10.8%,n=22)。代谢改善导致雷美索和腺苷蛋氨酸治疗后在重症监护病房的停留时间分别减少5.6±0.3天和7.3±0.6天。治疗总时长分别减少了9.0±0.4天和11.8±1.1天。与腺苷蛋氨酸相比,使用雷美索使治疗成本降低了21.7%。